Therapeutically blocking interleukin-11 receptor-α enhances doxorubicin cytotoxicity in high grade type I endometrioid tumours
Metrics: PDF 1471 views | HTML 1925 views | ?
Amy Winship1,2, Michelle Van Sinderen1,2, Katarzyna Rainczuk1,2, Evdokia Dimitriadis1,2,3
1Centre for Reproductive Health, The Hudson Institute of Medical Research, Clayton, 3168, VIC, Australia
2Department of Molecular and Translational Medicine, Monash University, Clayton, 3800, VIC, Australia
3Department of Anatomy and Developmental Biology, Monash University, Clayton, 3800, VIC, Australia
Evdokia Dimitriadis, email: [email protected]
Keywords: endometrioid, cytokine, chemotherapy
Received: November 10, 2016 Accepted: January 24, 2017 Published: February 08, 2017
High grade type I endometrial cancers have poor prognosis. Interleukin (IL)11 is elevated in tumours and uterine lavage with increasing tumour grade in women. IL11 regulates cell cycle, invasion and migration and we recently demonstrated that IL11 receptor (R)α inhibition impaired low and moderate grade endometrial tumourigenesis in vivo. In this report, we hypothesized that micro-RNA(miR)-1 regulates IL11 and that IL11 promotes high grade endometrial tumour growth. We aimed to determine whether combination treatment using an anti-human IL11Rα blocking antibody (Ab) and doxorubicin chemotherapeutic impairs high grade tumour growth. MiR-1 was absent in human endometrial tumours versus human benign endometrium (n = 10/group). Transfection with miR-1 mimic restored miR-1 expression, down-regulated IL11 mRNA and impaired cell viability in grade 3-derived AN3CA human endometrial epithelial cancer cells. AN3CA cell proliferation was reduced in response to Ab and doxorubicin combination treatment versus Ab, IgG control, or doxorubicin alone. Subcutaneous xenograft tumours were established in female Balb/c athymic nude mice using AN3CA cells expressing IL11 and IL11Rα. Administration of recombinant human IL11 to mice (n = 4/group) activated IL11 downstream target, signal transducers and activators of transcription (STAT3) and significantly increased tumour growth (p < 0.05), suggesting that IL11 promotes high grade tumour growth. IL11Rα blocking Ab reduced STAT3 phosphorylation and combination treatment with doxorubicin resulted in a significant reduction in tumour growth (p < 0.05) compared to Ab, doxorubicin, or IgG control. Our data suggest that therapeutically targeting IL11Rα in combination with doxorubicin chemotherapy could inhibit high grade type I endometrioid cancer growth.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.